DHVI Receives Contract to Manufacture Investigational Avian Flu Vaccines
The Duke Human Vaccine Institute received funding from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, to manufacture H5N1 avian flu vaccines for use in clinical trials.
NIAID recently funded $7 million to Duke under the contract called the Collaborative Influenza Vaccine Innovation Centers (CIVICs), which NIAID set up to develop new influenza vaccines that induce long-lasting immunity and protect against more variants of the virus.